This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Muralidharan, G.
Right arrow Articles by Troy, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Muralidharan, G.
Right arrow Articles by Troy, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, January 2005, p. 220-229, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.220-229.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Pharmacokinetics of Tigecycline after Single and Multiple Doses in Healthy Subjects

Gopal Muralidharan,{dagger} Marlynne Micalizzi, John Speth, Donald Raible, and Steven Troy*

Clinical Research, Wyeth Research, Collegeville, Pennsylvania

Received 21 June 2004/ Returned for modification 19 July 2004/ Accepted 22 September 2004

Tigecycline, a novel glycylcycline antibiotic, exhibits strong activity against gram-positive, gram-negative, aerobic, anaerobic, and atypical bacterial species, including many resistant pathogens, i.e., vancomycin-resistant enterococci, methicillin-resistant Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae. The safety and tolerability of tigecycline administered as single or multiple doses or at various infusion rates were explored in three phase 1, randomized, double-blind, placebo-controlled studies in healthy subjects. Full pharmacokinetic profiles of tigecycline were determined in two of these studies. Subjects in the single-dose study received 12.5 to 300 mg of tigecycline, which differed with respect to the duration of infusion, subjects' feeding status, and ondansetron pretreatment. Subjects in the ascending multiple-dose study received 25 to 100-mg doses of tigecycline as a 1-h infusion every 12 h. The variable volume and infusion rate study consisted of administration of 100-mg loading dose of tigecycline, followed by 50 mg every 12 h for 5 days. Serum samples were analyzed for tigecycline by validated high-pressure liquid chromatography or liquid chromatography/tandem mass spectrometry methods. Systemic clearance ranged from 0.2 to 0.3 liters/h/kg, and the tigecycline half-life ranged from 37 to 67 h. Tigecycline had a large volume of distribution (7 to 10 liters/kg), indicating extensive distribution into the tissues. Food increased the maximum tolerated single-dose from 100 to 200 mg, but the duration of infusion did not affect tolerability. Side effects, mainly nausea and vomiting, which are common to the tetracycline class of antimicrobial agents, were seen in these studies. Tigecycline exhibits linear pharmacokinetics and is safe and well tolerated in the dose ranges examined.

* Corresponding author. Mailing address: Wyeth Research, 500 Arcola Rd., Collegeville, PA 19426. Phone: (484) 865-5725. Fax: (484) 865-0058. E-mail: troys{at}wyeth.com.

{dagger} Present address: Lotus Labs, Bangalore 560 095, India.

Antimicrobial Agents and Chemotherapy, January 2005, p. 220-229, Vol. 49, No. 1
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.1.220-229.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Alou, L., Gimenez, M.-J., Cafini, F., Aguilar, L., Sevillano, D., Gonzalez, N., Torrico, M., Prieto, J., Garcia-Rey, C., Garcia-Escribano, N. (2009). In vitro effect of physiological concentrations of human albumin on the antibacterial activity of tigecycline. J Antimicrob Chemother 64: 1230-1233 [Abstract] [Full Text]  
  • Koomanachai, P., Crandon, J. L., Banevicius, M. A., Peng, L., Nicolau, D. P. (2009). Pharmacodynamic Profile of Tigecycline against Methicillin-Resistant Staphylococcus aureus in an Experimental Pneumonia Model. Antimicrob. Agents Chemother. 53: 5060-5063 [Abstract] [Full Text]  
  • Zhanel, G. G., Baudry, P. J., Tailor, F., Cox, L., Hoban, D. J., Karlowsky, J. A. (2009). Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum {beta}-lactamases, AmpC {beta}-lactamases and reduced susceptibility to carbapenems using an in vitro model. J Antimicrob Chemother 64: 824-828 [Abstract] [Full Text]  
  • Crandon, J. L., Kim, A., Nicolau, D. P. (2009). Comparison of tigecycline penetration into the epithelial lining fluid of infected and uninfected murine lungs. J Antimicrob Chemother 64: 837-839 [Abstract] [Full Text]  
  • Starzengruber, P., Thriemer, K., Haque, R., Khan, W. A., Fuehrer, H. P., Siedl, A., Hofecker, V., Ley, B., Wernsdorfer, W. H., Noedl, H. (2009). Antimalarial Activity of Tigecycline, a Novel Glycylcycline Antibiotic. Antimicrob. Agents Chemother. 53: 4040-4042 [Abstract] [Full Text]  
  • Vaudaux, P., Fleury, B., Gjinovci, A., Huggler, E., Tangomo-Bento, M., Lew, D. P. (2009). Comparison of Tigecycline and Vancomycin for Treatment of Experimental Foreign-Body Infection Due to Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 53: 3150-3152 [Abstract] [Full Text]  
  • Nicasio, A. M., Crandon, J. L., Nicolau, D. P. (2009). In Vivo Pharmacodynamic Profile of Tigecycline against Phenotypically Diverse Escherichia coli and Klebsiella pneumoniae Isolates. Antimicrob. Agents Chemother. 53: 2756-2761 [Abstract] [Full Text]  
  • Koomanachai, P., Kim, A., Nicolau, D. P. (2009). Pharmacodynamic evaluation of tigecycline against Acinetobacter baumannii in a murine pneumonia model. J Antimicrob Chemother 63: 982-987 [Abstract] [Full Text]  
  • Crandon, J. L., Banevicius, M. A., Nicolau, D. P. (2009). Pharmacodynamics of Tigecycline against Phenotypically Diverse Staphylococcus aureus Isolates in a Murine Thigh Model. Antimicrob. Agents Chemother. 53: 1165-1169 [Abstract] [Full Text]  
  • Livermore, D. M., Hope, R., Brick, G., Lillie, M., Reynolds, R., on behalf of the BSAC Working Parties on Resistanc, (2008). Non-susceptibility trends among Enterobacteriaceae from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62: ii41-ii54 [Abstract] [Full Text]  
  • Livermore, D. M., Hope, R., Brick, G., Lillie, M., Reynolds, R., on behalf of the BSAC Working Parties on Resistanc, (2008). Non-susceptibility trends among Pseudomonas aeruginosa and other non-fermentative Gram-negative bacteria from bacteraemias in the UK and Ireland, 2001-06. J Antimicrob Chemother 62: ii55-ii63 [Abstract] [Full Text]  
  • (2008). What role for {blacktriangledown}tigecycline in infections?. DTB 46: 62-64 [Abstract] [Full Text]  
  • Karageorgopoulos, D. E., Kelesidis, T., Kelesidis, I., Falagas, M. E. (2008). Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Acinetobacter infections: a review of the scientific evidence. J Antimicrob Chemother 62: 45-55 [Abstract] [Full Text]  
  • Passarell, J. A., Meagher, A. K., Liolios, K., Cirincione, B. B., Van Wart, S. A., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2008). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Intra-Abdominal Infections. Antimicrob. Agents Chemother. 52: 204-210 [Abstract] [Full Text]  
  • Rubino, C. M., Ma, L., Bhavnani, S. M., Korth-Bradley, J., Speth, J., Ellis-Grosse, E., Rodvold, K. R., Ambrose, P. G., Drusano, G. L. (2007). Evaluation of Tigecycline Penetration into Colon Wall Tissue and Epithelial Lining Fluid Using a Population Pharmacokinetic Model and Monte Carlo Simulation. Antimicrob. Agents Chemother. 51: 4085-4089 [Abstract] [Full Text]  
  • Hoffmann, M., DeMaio, W., Jordan, R. A., Talaat, R., Harper, D., Speth, J., Scatina, J. (2007). Metabolism, Excretion, and Pharmacokinetics of [14C]Tigecycline, a First-In-Class Glycylcycline Antibiotic, after Intravenous Infusion to Healthy Male Subjects. Drug Metab. Dispos. 35: 1543-1553 [Abstract] [Full Text]  
  • Meagher, A. K., Passarell, J. A., Cirincione, B. B., Van Wart, S. A., Liolios, K., Babinchak, T., Ellis-Grosse, E. J., Ambrose, P. G. (2007). Exposure-Response Analyses of Tigecycline Efficacy in Patients with Complicated Skin and Skin-Structure Infections. Antimicrob. Agents Chemother. 51: 1939-1945 [Abstract] [Full Text]  
  • Van Wart, S. A., Cirincione, B. B., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Owen, J. S. (2007). Population Pharmacokinetics of Tigecycline in Healthy Volunteers. J Clin Pharmacol 47: 727-737 [Abstract] [Full Text]  
  • Slover, C. M, Rodvold, K. A, Danziger, L. H (2007). Tigecycline: A Novel Broad-Spectrum Antimicrobial. The Annals of Pharmacotherapy 41: 965-972 [Abstract] [Full Text]  
  • Scheetz, M. H., Qi, C., Warren, J. R., Postelnick, M. J., Zembower, T., Obias, A., Noskin, G. A. (2007). In Vitro Activities of Various Antimicrobials Alone and in Combination with Tigecycline against Carbapenem-Intermediate or -Resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 51: 1621-1626 [Abstract] [Full Text]  
  • Maclayton, D. O, Hall II, R. G (2007). Pharmacologic Treatment Options for Nosocomial Pneumonia Involving Methicillin-Resistant Staphylococcus aureus. The Annals of Pharmacotherapy 41: 235-244 [Abstract] [Full Text]  
  • Rodvold, K. A., Gotfried, M. H., Cwik, M., Korth-Bradley, J. M., Dukart, G., Ellis-Grosse, E. J. (2006). Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J Antimicrob Chemother 58: 1221-1229 [Abstract] [Full Text]  
  • Van Wart, S. A., Owen, J. S., Ludwig, E. A., Meagher, A. K., Korth-Bradley, J. M., Cirincione, B. B. (2006). Population Pharmacokinetics of Tigecycline in Patients with Complicated Intra-Abdominal or Skin and Skin Structure Infections. Antimicrob. Agents Chemother. 50: 3701-3707 [Abstract] [Full Text]  
  • Nord, C. E., Sillerstrom, E., Wahlund, E. (2006). Effect of tigecycline on normal oropharyngeal and intestinal microflora.. Antimicrob. Agents Chemother. 50: 3375-3380 [Abstract] [Full Text]  
  • Agwuh, K. N., MacGowan, A. (2006). Pharmacokinetics and pharmacodynamics of the tetracyclines including glycylcyclines. J Antimicrob Chemother 58: 256-265 [Abstract] [Full Text]  
  • Kasbekar, N. (2006). Tigecycline: A new glycylcycline antimicrobial agent.. Am J Health Syst Pharm 63: 1235-1243 [Abstract] [Full Text]  
  • Thamlikitkul, V., Trakulsomboon, S. (2006). In Vitro Activity of Tigecycline against Burkholderia pseudomallei and Burkholderia thailandensis.. Antimicrob. Agents Chemother. 50: 1555-1557 [Abstract] [Full Text]  
  • Livermore, D. M. (2005). Tigecycline: what is it, and where should it be used?. J Antimicrob Chemother 56: 611-614 [Abstract] [Full Text]  
  • Ong, C. T., Babalola, C. P., Nightingale, C. H., Nicolau, D. P. (2005). Penetration, efflux and intracellular activity of tigecycline in human polymorphonuclear neutrophils (PMNs). J Antimicrob Chemother 56: 498-501 [Abstract] [Full Text]  
  • Muralidharan, G., Fruncillo, R. J., Micalizzi, M., Raible, D. G., Troy, S. M. (2005). Effects of Age and Sex on Single-Dose Pharmacokinetics of Tigecycline in Healthy Subjects. Antimicrob. Agents Chemother. 49: 1656-1659 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»